Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Cancer Center, Korea
Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients.
* Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA extracted from collected patient samples.
* Correlation analysis of KRAS mutation results with clinical data.
Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.
* Gene panel composition for pancreatic cancer therapeutic target determination and monitoring.
* A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic cancer patients.
* Comparative analysis of panel results and quantitative KRAS mutations and evaluation of clinical applicability.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with pathologically confirmed pancreatic adenocarcinoma.
You may not be if
Patients disagree with the study.
Clareo Health | Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy
